Related Experiment Videos
SGLT2 Inhibitors and Uric Acid Homeostasis
1Department of Physiology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Gout, Urate, and Crystal Deposition Disease
|August 13, 2026
Summary
Sodium-glucose transporter 2 inhibitors (SGLT2i) lower uric acid levels, benefiting patients with metabolic disorders like type 2 diabetes. Further research is needed to understand the exact mechanisms behind this uricosuric effect.
Area of Science:
- Nephrology
- Endocrinology
- Metabolic Disorders
Background:
- A link between metabolic disorders and hyperuricemia is known, but the precise relationship is unclear.
- Hyperuricemia is a common comorbidity in type 2 diabetes mellitus (T2D).
- Sodium-glucose transporter 2 inhibitors (SGLT2i) offer benefits for hyperglycemia, T2D, and associated cardio-renal conditions.
Purpose of the Study:
- To review the renal physiology of glucose and uric acid transport.
- To discuss the renal consequences of hyperglycosuria and diabetes.
- To explore potential mechanisms for the uricosuric effect of SGLT2i.
Main Methods:
- Literature review of renal physiology.
- Analysis of SGLT2i effects on glucose and uric acid.
- Discussion of potential uricosuric mechanisms.
Main Results:
- SGLT2i treatment is associated with reduced plasma uric acid levels.
- SGLT2i treatment increases urinary uric acid excretion (uricosuria).
- The exact mechanisms driving these uricosuric effects require further elucidation.
Conclusions:
- SGLT2i may hold potential as a therapeutic option for gout and hyperuricemia.
- Understanding SGLT2i's uricosuric mechanisms could optimize treatment strategies.
- Further investigation into SGLT2i's renal effects is warranted.
Related Concept Videos
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:24Phase II Reactions: Glucuronidation
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
01:30Urinary Tract Calculi III: Medical Management
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...